20.65

2.04% 0.32

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is traded at $20.65, with a volume of 674.61K. It is up +2.04% in the last 24 hours and up +19.43% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Previous Close:

$20.33

Open:

$20.31

24h Volume:

674.61K

Relative Volume:

0.39

Market Cap:

$3.41B

Revenue:

Net Income/Loss:

$-451.71M

P/E Ratio:

-6.4009

EPS:

-3.2261

Net Cash Flow:

$-462.19M

1W Performance:

+4.77%

1M Performance:

+19.43%

6M Performance:

+1.94%

1Y Performance:

+99.09%

1-Day Range:

$20.25

$21.25

1-Week Range:

$20.11

$21.54

52-Week Range:

$8.06

$25.00

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (619)

Phone

(781) 786-8230

Address

1560 TRAPELO ROAD, WALTHAM

Employee

258

Twitter

Next Earnings Date

2026-07-27

Latest SEC Filings

DYN's Discussions on Twitter

Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DYN Dyne Therapeutics Inc	20.65	3.36B	0	-451.71M	-462.19M	-3.2261
VRTX Vertex Pharmaceuticals Inc	483.61	120.61B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	626.23	65.36B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.23	53.02B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.61	39.26B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	176.29	36.09B	742.00K	-1.37B	-1.07B	-7.0731

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy
Jun-24-25	Initiated	Bernstein	Mkt Perform
Jun-11-25	Resumed	Raymond James	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-29-25	Initiated	Evercore ISI	Outperform
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-13-24	Initiated	Robert W. Baird	Outperform
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral
May-21-24	Reiterated	Chardan Capital Markets	Buy
Apr-30-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	H.C. Wainwright	Buy
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

Jun 24, 2026

Dyne Therapeutics director Kersten sells $5.46 million in shares By Investing.com - Investing.com Australia

Jun 24, 2026

Dyne Therapeutics director Kersten sells $5.46 million in shares - Investing.com UK

Jun 24, 2026

Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria

Jun 24, 2026

Form 144 Dyne Therapeutics For: 24 June By Investing.com - Investing.com South Africa

Jun 24, 2026

Dyne Therapeutics(DYN.US) Director Sells US$5.46 Million in Common Stock - Moomoo

Jun 24, 2026

Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing - marketscreener.com

Jun 24, 2026

Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan - Stock Titan

Jun 24, 2026

Dyne Therapeutics (DYN) Expands Term Loan Facility with Hercules Capital by $400M to Advance Clinical Pipeline - Insider Monkey

Jun 24, 2026

Jun 23, 2026

Form 144 Dyne Therapeutics For: 23 June By Investing.com - Investing.com Nigeria

Jun 23, 2026

[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan

Jun 23, 2026

Director at Dyne Therapeutics (DYN) awarded 57,463 stock options vesting over 3 years - Stock Titan

Jun 23, 2026

Dyne Therapeutics (NASDAQ: DYN) director Barry Greene files initial Form 3 - Stock Titan

Jun 23, 2026

Dyne Therapeutics appoints Barry Greene to board of directors - Investing.com UK

Jun 23, 2026

Dyne Therapeutics appoints Barry Greene to board of directors By Investing.com - Investing.com South Africa

Jun 23, 2026

Jun 22, 2026

Dyne Therapeutics Appoints Barry Greene to Board of Directors - Investing News Network

Jun 22, 2026

Dyne Therapeutics elects Barry E. Greene to Board as Class I director - TradingView

Jun 22, 2026

Barry Greene joins Dyne Therapeutics (DYN) board with new option grant - Stock Titan

Jun 22, 2026

Entity tied to Dyne (DYN) director sells 84K pre-planned shares - Stock Titan

Jun 22, 2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 18, 2026 - marketscreener.com

Jun 22, 2026

Jun 19, 2026

Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr

Jun 19, 2026

Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com

Jun 19, 2026